217 related articles for article (PubMed ID: 3304898)
1. Miscibility of human semisynthetic regular and lente insulin and human biosynthetic regular and NPH insulin.
Olsson PO; Hans A; Henning VS
Diabetes Care; 1987; 10(4):473-7. PubMed ID: 3304898
[TBL] [Abstract][Full Text] [Related]
2. The contribution of intermediate-acting insulin preparations to daytime insulin treatment.
Robert JJ; Chevenne D; Debray M
Diabet Med; 1989 Aug; 6(6):531-6. PubMed ID: 2527136
[TBL] [Abstract][Full Text] [Related]
3. Different daily blood glucose control and free insulin levels during treatment with mixtures of soluble and lente or soluble and NPH semisynthetic human insulins.
Cucinotta D; Di Benedetto A; Gigante A; Di Cesare E; Musolino C; Squadrito G
Diabete Metab; 1989; 15(4):182-7. PubMed ID: 2680669
[TBL] [Abstract][Full Text] [Related]
4. Assessing effect of mixing insulins by glucose-clamp technique in subjects with diabetes mellitus.
Colagiuri S; Villalobos S
Diabetes Care; 1986; 9(6):579-86. PubMed ID: 3542452
[TBL] [Abstract][Full Text] [Related]
5. Intermediate-acting insulin preparations: NPH and lente.
Deckert T
Diabetes Care; 1980; 3(5):623-6. PubMed ID: 7192205
[TBL] [Abstract][Full Text] [Related]
6. The clinical effects of mixing short- and intermediate-acting insulins in the treatment of non-insulin-dependent diabetes.
Best JD; Ley CJ; Strauss BJ; Alford FP; Aitken PM
Med J Aust; 1987 Jun; 146(12):621-3, 627. PubMed ID: 3306298
[TBL] [Abstract][Full Text] [Related]
7. Absorption kinetics and action profiles of mixtures of short- and intermediate-acting insulins.
Heine RJ; Bilo HJ; Fonk T; van der Veen EA; van der Meer J
Diabetologia; 1984 Dec; 27(6):558-62. PubMed ID: 6397384
[TBL] [Abstract][Full Text] [Related]
8. Double-blind crossover trial of isophane (NPH)- and lente-based insulin regimens.
Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I
Diabetes Care; 1989 Feb; 12(2):115-9. PubMed ID: 2649324
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures.
Galloway JA; Spradlin CT; Nelson RL; Wentworth SM; Davidson JA; Swarner JL
Diabetes Care; 1981; 4(3):366-76. PubMed ID: 7047113
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent subcutaneous absorption of porcine, bovine and human NPH insulins.
Hildebrandt P; Birch K; Sestoft L; Vølund A
Acta Med Scand; 1984; 215(1):69-73. PubMed ID: 6364700
[TBL] [Abstract][Full Text] [Related]
11. [Advances in insulin treatment. Evaluation of isophane or lente insulin, mixed with rapid insulin and injected twice-a-day].
Cucinotta D; Lunetta M
Minerva Endocrinol; 1990; 15(2):111-6. PubMed ID: 2098651
[TBL] [Abstract][Full Text] [Related]
12. Reduced solubility of short-acting soluble insulins when mixed with longer-acting insulins.
Nolte MS; Poon V; Grodsky GM; Forsham PH; Karam JH
Diabetes; 1983 Dec; 32(12):1177-81. PubMed ID: 6360762
[TBL] [Abstract][Full Text] [Related]
13. Mixing short and intermediate acting insulins in the syringe: effect on postprandial blood glucose concentrations in type I diabetics.
Heine RJ; Bilo HJ; Sikkenk AC; van der Veen EA
Br Med J (Clin Res Ed); 1985 Jan; 290(6463):204-5. PubMed ID: 3917752
[No Abstract] [Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
[TBL] [Abstract][Full Text] [Related]
15. Circadian profiles of blood glucose and plasma free insulin during treatment with semisynthetic and biosynthetic human insulin, and comparison with conventional monocomponent preparations.
Castillo M; Nemery A; Verdin E; Lefebvre PJ; Luyckx AS
Eur J Clin Pharmacol; 1983; 25(6):767-71. PubMed ID: 6363099
[TBL] [Abstract][Full Text] [Related]
16. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin.
Joseph SE; Korzon-Burakowska A; Woodworth JR; Evans M; Hopkins D; Janes JM; Amiel SA
Diabetes Care; 1998 Dec; 21(12):2098-102. PubMed ID: 9839100
[TBL] [Abstract][Full Text] [Related]
17. Mixtures of human intermediate and human regular insulin in type 1 diabetic patients. Evaluation of free insulin levels and insulin action on glucose metabolism after combined and separate subcutaneous administration.
Klauser R; Schernthaner G; Prager R
Diabetes Res Clin Pract; 1988 Sep; 5(3):185-90. PubMed ID: 3065016
[TBL] [Abstract][Full Text] [Related]
18. Delayed onset of action of soluble insulin after premixing with U100 lente insulin.
Heine RJ; Sikkenk AC; Eizenga WH; van der Veen EA
Diabetes Res Clin Pract; 1986; 2(6):353-8. PubMed ID: 3545725
[TBL] [Abstract][Full Text] [Related]
19. Study of porcine and human isophane (NPH) insulins in normal subjects.
Owens DR; Jones IR; Birtwell AJ; Burge CT; Luzio S; Davies CJ; Heyburn P; Heding LG
Diabetologia; 1984 Apr; 26(4):261-5. PubMed ID: 6376233
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the activity profiles of two fixed combinations of regular/NPH human insulin (recombinant DNA) of different compositions with a fixed regular/NPH porcine insulin combination (PPI) in insulin-dependent diabetic individuals.
Sailer D; Ludwig T; Kolb S
Diabetes Care; 1982; 5 Suppl 2():57-9. PubMed ID: 6765542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
